Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1.86 USD
Change Today +0.11 / 6.29%
Volume 205.8K
PTIE On Other Exchanges
PTIE is not on other exchanges.
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

pain therapeutics inc (PTIE) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/2/14 - $4.50
52 Week Low
08/6/15 - $1.53
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for PAIN THERAPEUTICS INC (PTIE)

pain therapeutics inc (PTIE) Related Businessweek News

No Related Businessweek News Found

pain therapeutics inc (PTIE) Details

Pain Therapeutics, Inc., a biopharmaceutical company, develops novel drugs in the United States. The company’s lead drug candidate is REMOXY, an extended-release oral formulation of oxycodone for the management of moderate-to-severe pain when a continuous and around-the-clock opioid analgesic is needed. It also develops abuse-resistant formulation of hydromorphone; and FENROCK, a proprietary abuse-deterrent transdermal pain patch for pain relief. The company has strategic alliance with Pfizer, Inc. to develop and commercialize REMOXY. Pain Therapeutics, Inc. was founded in 1998 and is based in Austin, Texas.

9 Employees
Last Reported Date: 02/18/15
Founded in 1998

pain therapeutics inc (PTIE) Top Compensated Officers

Founder, Chairman, Chief Executive Officer an...
Total Annual Compensation: $767.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $338.5K
Chief Operating Officer, Chief Medical Office...
Total Annual Compensation: $283.5K
Independent Consultant and Member of Scientif...
Total Annual Compensation: $323.5K
Compensation as of Fiscal Year 2014.

pain therapeutics inc (PTIE) Key Developments

Pain Therapeutics Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Net Cash Usage Guidance for the Year 2015

Pain Therapeutics Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported net loss was $3.374 million or $0.07 per basic and diluted share against net loss of $3.246 million or $0.07 per basic and diluted share a year ago. Operating loss was $3.387 million against $3.257 million a year ago. For the six months, the company reported net loss was $5.597 million or $0.13 per basic and diluted share against net loss of $6.695 million or $0.15 per basic and diluted share a year ago. Operating loss was $5.982 million against $6.72 million a year ago. The Company continues to expects net cash usage in 2015 may be approximately $12 million.

Pain Therapeutics Seeks Acquisitions

Pain Therapeutics Inc. (NasdaqGS:PTIE) is seeking acquisitions. Pain Therapeutics expects to continue to use significant cash resources to acquire or in-license additional products or technologies.

Pain Therapeutics Inc. Provides Update on Class Action Suit

On December 2, 2011, a securities-related purported class action was filed against Pain Therapeutics Inc. and its executive officers in the U.S. District Court for the Western District of Texas. This action, titled KB Partners I, L.P., Individually and on behalf of all others similarly situated v. Pain Therapeutics Inc., Remi Barbier, Nadav Friedmann and Peter S. Roddy, was scheduled for trial by court order dated June 23, 2015. Trial is to occur on July 7, 2015 through July 9, 2015 and continue on July 13, 2015 to July 14, 2015. In an order dated June 16, 2015, the U.S. District Court for the Western District of Texas denied a motion for summary judgment filed by Defendants concluding that there were genuine disputes of material fact for a jury to resolve in a class action alleging violations of Section 10(b), Rule 10b-5, and Section 20(a) of the Exchange Act. The company continue to believe it has substantial defenses in this matter. As with any litigation proceeding, it cannot predict with certainty the eventual outcome of this matter.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PTIE:US $1.86 USD +0.11

PTIE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PTIE.
View Industry Companies

Industry Analysis


Industry Average

Valuation PTIE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PAIN THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at